Alveus Therapeutics has made its debut following a successful $160 million Series A financing round. Led by prominent healthcare investors including New Rhein Healthcare Investors, Andera Partners, and Omega Funds, the capital injection aims to challenge the current obesity treatment landscape with innovative biological solutions.
Breakthrough technology and clinical objectives Alveus distinguishes itself by focusing on amylin biology and fusion proteins. The company’s pipeline features two primary assets:
-
ALV-100: A bifunctional fusion protein (GIP receptor antagonist and GLP-1 receptor agonist). This candidate is designed to address the “weight-loss plateau” often experienced by patients on existing therapies.
-
ALV-200: An amylin receptor 3 (AMYR3) peptide agonist, currently in the IND-enabling stage.
Leadership team from pharmaceutical giants The company’s momentum is bolstered by a leadership team comprising former heads of cardiometabolic divisions from Eli Lilly and Novo Nordisk. The expertise of these industry veterans is expected to help Alveus streamline the trajectory from concept to commercialization.
The Series A proceeds will primarily support Phase II clinical development for ALV-100 and advance several other early-stage candidates in both injectable and oral formats.